BR112023002295A2 - Terapia de combinação - Google Patents

Terapia de combinação

Info

Publication number
BR112023002295A2
BR112023002295A2 BR112023002295A BR112023002295A BR112023002295A2 BR 112023002295 A2 BR112023002295 A2 BR 112023002295A2 BR 112023002295 A BR112023002295 A BR 112023002295A BR 112023002295 A BR112023002295 A BR 112023002295A BR 112023002295 A2 BR112023002295 A2 BR 112023002295A2
Authority
BR
Brazil
Prior art keywords
combination
combination therapy
erapy
antiandrogen
cdk4
Prior art date
Application number
BR112023002295A
Other languages
English (en)
Inventor
Anders Lars
Hyunjung Kim Kimberly
Li Danan
Anne Mcmillan Elizabeth
Andrew Rollins Robert
Ayers Veeneman Brendan
Original Assignee
Pfizer
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Astellas Pharma Inc filed Critical Pfizer
Publication of BR112023002295A2 publication Critical patent/BR112023002295A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

ERAPIA DE COMBINAÇÃO. A presente invenção refere-se a terapias de combinação compreendendo um inibidor de cinase 4 dependente de ciclina (CDK4) de Fórmula (I) ou um sal farmaceuticamente aceitável do mesmo, e um antiandrogênio, opcionalmente em combinação adicional com um agente anticancerígeno adicional e métodos associados de tratamento, composições farmacêuticas e usos dos mesmos.
BR112023002295A 2020-08-13 2021-08-10 Terapia de combinação BR112023002295A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063065160P 2020-08-13 2020-08-13
PCT/IB2021/057379 WO2022034504A1 (en) 2020-08-13 2021-08-10 Combination therapy

Publications (1)

Publication Number Publication Date
BR112023002295A2 true BR112023002295A2 (pt) 2023-03-14

Family

ID=77398611

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002295A BR112023002295A2 (pt) 2020-08-13 2021-08-10 Terapia de combinação

Country Status (11)

Country Link
US (1) US20240000783A1 (pt)
EP (1) EP4196126A1 (pt)
JP (1) JP2023537595A (pt)
KR (1) KR20230057384A (pt)
CN (1) CN116322693A (pt)
AU (1) AU2021325426A1 (pt)
BR (1) BR112023002295A2 (pt)
CA (1) CA3188821A1 (pt)
IL (1) IL300581A (pt)
MX (1) MX2023001823A (pt)
WO (1) WO2022034504A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023100070A1 (en) * 2021-12-02 2023-06-08 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
CN115068421B (zh) * 2022-08-03 2023-08-04 南昌大学 一种瑞卢戈利纳米混悬液及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035298A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing gum containing medicament active agents
ES2535179T3 (es) 2005-05-13 2015-05-06 The Regents Of The University Of California Compuesto de diarilhidantoína como antagonistas de los receptores de andrógenos para el tratamiento de cáncer
DK2368550T3 (da) 2006-03-27 2013-09-30 Univ California Androgenreceptormodulator til behandlingen af prostatakræft og androgenreceptor-associerede sygdomme
RU2548918C2 (ru) 2009-02-24 2015-04-20 Медивэйшн Простейт Терапьютикс, Инк. Специфические соединения диарилгидантоина и диарилтиогидантоина
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
RU2434851C1 (ru) 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
CN103159680A (zh) 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
BR112020013915A2 (pt) * 2018-01-08 2020-12-01 G1 Therapeutics, Inc. regime de dosagem para liberação, e, método para tratar um câncer dependente de replicação de cdk4/6 em um humano
UA126177C2 (uk) 2018-04-26 2022-08-25 Пфайзер Інк. Похідні 2-амінопіридину або 2-амінопіримідину як інгібітори циклінзалежної кінази

Also Published As

Publication number Publication date
US20240000783A1 (en) 2024-01-04
MX2023001823A (es) 2023-03-13
CN116322693A (zh) 2023-06-23
EP4196126A1 (en) 2023-06-21
AU2021325426A1 (en) 2023-03-09
CA3188821A1 (en) 2022-02-17
IL300581A (en) 2023-04-01
WO2022034504A1 (en) 2022-02-17
JP2023537595A (ja) 2023-09-04
KR20230057384A (ko) 2023-04-28

Similar Documents

Publication Publication Date Title
BR112021009595A2 (pt) Terapia de combinação incluindo um inibidor de krasg12c e um ou mais agentes farmaceuticamente ativos adicionais para o tratamento de cânceres
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BR112023002295A2 (pt) Terapia de combinação
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
BR112022009571A2 (pt) Uso de inibidor de fak na preparação de um fármaco para tratar tumores que têm mutação nras
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
NZ630589A (en) Methods of treating alzheimer’s disease and pharmaceutical compositions thereof
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112015011171A2 (pt) compostos de pirrolopirimidina como inibidores da quinase
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
BRPI0714055B8 (pt) compostos moduladores de propriedades farmacocinéticas de terapêuticos, composições farmacêuticas que compreendem os referidos compostos e usos dos mesmo
BRPI0517104A (pt) tratamento combinado com bortezomib e um inibidor de cinase de receptor de fator de crescimento epidérmico
PA8627601A1 (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-ilo]-(4-bromo-3-metil-5-propoxi-tiofen-2-ilo)-metanona hidrocloruro como un inhibidor de triptasa de mastocitos
BRPI0511800A (pt) tratamento com irinotecano (cpt-11) e um inibidor de egfr
RS20080497A (en) Novel low dose pharmaceutical compositions comrising nimesulide, preparation and use thereof
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
PH12020500099A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a cyclin d kinase inhibitor
BR112021023110A2 (pt) Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
MX2021013641A (es) Derivados de ftalazina como inhibidores de parp1, parp2 y/o tubulina utiles para el tratamiento del cancer.
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
BR112019002945A2 (pt) terapia de combinação para o tratamento de câncer pancreático
BRPI0511780A (pt) tratamento com oxoliplatina e um inibidor de egrf
BR112022006394A2 (pt) Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer